engleski

Hypolipemics usage in Croatia

INTRODUCTION Cardiovascular diseases (CVD) as leading single cause of death in Croatia have huge economic impact on healthcare resources. The impact is elevated and expected to escalate. Statins reduce the risk of CVDs, but the impact of their costs to the healthcare budgets is relatively high. The aim of our study was to identify and analyze changes in the usage of these drugs in Croatia from 2000- 2016 and to identify the changes in the average price for 1 DDD. MATERIALS AND METHODS Data on the consumption have been obtained from the database IMS (International Medical Statistics). According to the World Health Organization Collaborating Centre for Drugs Statistics Methodology annual volumes of drugs are presented in defined daily doses/1000 inhabitants/day (DDD/1000), while financial expenditure data are presented in Euros (€). RESULTS While the total consumption of CV drugs during investigated period raised from 190.176 DDD/1000 in 2000 to 476.981 DDD/1000 in 2016, the total consumption of statins raised more than 10 times in the same period, from 5.081 DDD/1000 to 70.006 DDD/1000 in 2016. Average price of statins was more than 5 times higher than the average price of CV drugs in 2000, but it decreased from 1.27 EUR/DDD in 2000 to 0.17 EUR/DDD in 2016, while the average price of CV drugs in 2016 was 0.14 EUR/DDD. The most prescribed statin in 2000 was simvastatin, and in 2016 atorvastatin and rosuvastatin. CONCLUSION Increased hypolipemics usage is comparable to worldwide trends, but the financial spending on lipid modifying agents in Croatia raised on slower rate than total prescription in DDDs. The average cost per DDD gradually decreased mainly as the result of the introduction of generics and the implementation of restrictive measures on the Croatian drug market. Prescription patterns among statins have changed during investigated period.

hypolipemics, drug usage, prescription patterns

nije evidentirano